HC Wainwright Lowers Emergent Biosolutions (NYSE:EBS) Price Target to $12.00
HC Wainwright decreased their target price on shares of Emergent Biosolutions from $15.00 to $12.00 and set a "buy" rating for the company in a research note on Monday...
MarketBeat·13d ago
More News
Emergent Biosolutions (NYSE:EBS) Cut to Hold at Wall Street Zen
Wall Street Zen downgraded shares of Emergent Biosolutions from a "buy" rating to a "hold" rating in a report on Sunday...
MarketBeat·14d ago
Wall Street Zen Downgrades Emergent Biosolutions (NYSE:EBS) to Buy
Wall Street Zen cut shares of Emergent Biosolutions from a "strong-buy" rating to a "buy" rating in a research report on Saturday...
MarketBeat·22d ago
Emergent Biosolutions Q4 Earnings Call Highlights
Emergent Biosolutions (NYSE:EBS) reported fourth-quarter and full-year 2025 results on a Feb. 26, 2026 earnings call, with management highlighting progress on its multi-year transformation plan...
MarketBeat·22d ago
Why Did Emergent Biosolutions Stock Tumble 20% After-Hours Today?
The board authorized a new $50 million share repurchase program running through March 2027.
Emergent Biosolutions (NYSE:EBS - Get Free Report) released its earnings results on Thursday. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing...
MarketBeat·24d ago
Emergent Biosolutions (EBS) Expected to Announce Earnings on Monday
Emergent Biosolutions (NYSE:EBS) will be releasing its Q4 2025 earnings after the market closes on Monday, March 2. (View Earnings Report at...
MarketBeat·27d ago
Emergent Biosolutions Inc. $EBS Shares Purchased by Allianz Asset Management GmbH
Allianz Asset Management GmbH grew its stake in shares of Emergent Biosolutions Inc. (NYSE:EBS - Free Report) by 149.0% during the 3rd quarter, according to the company in its most recent Form 13F...
MarketBeat·1mo ago
New York State Common Retirement Fund Has $4.60 Million Stock Holdings in Emergent Biosolutions Inc. $EBS
New York State Common Retirement Fund lifted its stake in shares of Emergent Biosolutions Inc. (NYSE:EBS - Free Report) by 32.6% in the third quarter, according to its most recent Form 13F filing...